The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA grants Orphan Drug Designation to cerdulatinib for the treatment of peripheral T-cell lymphoma
On 25 September 2018, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to cerdulatinib, an oral Syk/JAK inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL).
SYK is a key regulator of BCR signaling and it is also expressed in PTCL. Preclinical studies suggest that SYK may be an oncogenic driver for PTCL. Cerdulatinib is a selective and potent inhibitor of SYK, JAK1, JAK3, and TYK2.
At present, cerdulatinib is being evaluated in an ongoing phase IIb study (NCT01994382), which is assessing the efficacy and safety of cerdulatinib in patients with relapsed or refractory B- and T-cell lymphoma. Interim data presented at the 23rd Congress of the European Hematology Association (EHA) demonstrated that cerdulatinib exhibited broad clinical activity and was well tolerated. Seven of the 20 patients in the PTCL cohort achieved a complete response at the time of presentation.
References